Armstrong, A. J., Kemeny, G., Turnbull, J. D., Chao, C., Winters, C., Fesko, Y. A., … Garcia-Blanco, M. (2010). Impact of temsirolimus and anti-androgen therapy on circulating tumor cell (CTC) biology in men with castration-resistant metastatic prostate cancer (CRPC): A phase II study. Journal of Clinical Oncology, 28(15_suppl), TPS249–TPS249. https://doi.org/10.1200/jco.2010.28.15_suppl.tps249

Armstrong, A. J., G. Kemeny, J. D. Turnbull, C. Chao, C. Winters, Y. A. Fesko, D. A. Bradley, S. Halabi, D. J. George, and M. Garcia-Blanco. “Impact of temsirolimus and anti-androgen therapy on circulating tumor cell (CTC) biology in men with castration-resistant metastatic prostate cancer (CRPC): A phase II study.” Journal of Clinical Oncology 28, no. 15_suppl (May 20, 2010): TPS249–TPS249. https://doi.org/10.1200/jco.2010.28.15_suppl.tps249.

Armstrong AJ, Kemeny G, Turnbull JD, Chao C, Winters C, Fesko YA, et al. Impact of temsirolimus and anti-androgen therapy on circulating tumor cell (CTC) biology in men with castration-resistant metastatic prostate cancer (CRPC): A phase II study. Journal of Clinical Oncology. 2010 May 20;28(15_suppl):TPS249–TPS249.

Armstrong, A. J., et al. “Impact of temsirolimus and anti-androgen therapy on circulating tumor cell (CTC) biology in men with castration-resistant metastatic prostate cancer (CRPC): A phase II study.” Journal of Clinical Oncology, vol. 28, no. 15_suppl, American Society of Clinical Oncology (ASCO), May 2010, pp. TPS249–TPS249. Crossref, doi:10.1200/jco.2010.28.15_suppl.tps249.

Armstrong AJ, Kemeny G, Turnbull JD, Chao C, Winters C, Fesko YA, Bradley DA, Halabi S, George DJ, Garcia-Blanco M. Impact of temsirolimus and anti-androgen therapy on circulating tumor cell (CTC) biology in men with castration-resistant metastatic prostate cancer (CRPC): A phase II study. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2010 May 20;28(15_suppl):TPS249–TPS249.